Journals / Acta Medica / 2020 / Cilt: 51 - Sayı: 3

NK and Th17 Cells in The Thymus of Myasthenia Gravis Patients

Pages
9–17
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Both natural killer cells and Th17 cells are found in the myasthenic thymus indicating a possible cross-regulation between these cell types that may influence the course of autoimmune reactions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: As a classical autoimmune disorder, anti-acetylcholine receptor antibody positive myasthenia gravis has an unconventional pathophysiology that involves thymus, the central organ for immune tolerance induction.
📊
Key Findings & Data:Both natural cells and type 17 helper T (Th17) cells possess capacity to influence autoimmune inflammation.
💡
Conclusion & Impact:Conclusion: Both natural killer cells and Th17 cells are found in the myasthenic thymus indicating a possible cross-regulation between these cell types that may influence the course of autoimmune reactions.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: As a classical autoimmune disorder, anti-acetylcholine receptor antibody positive myasthenia gravis has an unconventional pathophysiology that involves thymus, the central organ for immune tolerance induction. Both natural cells and type 17 helper T (Th17) cells possess capacity to influence autoimmune inflammation. This study aims to determine the presence of Th17 and natural killer cells in the thymus from myasthenia gravis patients. Materials and Methods: Thymectomy materials of myasthenia gravis patients and non-myasthenic controls were assessed by CD56, CD16, CD2, CD3, NKG2D, NKp46 and IL-23R flow cytometry and IL-23R, IL-21R, and ROR-γ immunohistochemistry. Results: Even though natural killer cell infiltration was limited, the majority of these cells displayed activation markers NKG2D and NKp46. Expectedly, the amount of CD2+ lymphocytic cells were higher than CD3+ thymocytes in which a considerable percentage was carrying the receptor for IL-23 (IL-23R). In addition to IL-23R, IL21R, and ROR-γ were also detected in myasthenic thymus as a marker related to Th17 cells. These Th17-related markers were reduced in thymoma compared to that of detected in thymic hyperplasia or the myasthenic thymus with normal histopathology. Conclusion: Both natural killer cells and Th17 cells are found in the myasthenic thymus indicating a possible cross-regulation between these cell types that may influence the course of autoimmune reactions.

🔖

Cite This Article

ESENDAĞLI, G., KARABULUT, E., KURT, C. E. B., ÖZDAMAR, S. E., ÖNDER, S., MEHDIKHANOVA, L., TUNCER, A., TUNALI, G., YILMAZ, M. (2022). NK and Th17 Cells in The Thymus of Myasthenia Gravis Patients. Acta Medica, Cilt: 51 - Sayı: 3, 9–17. https://ajindex.com/articles/427549

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet. 2001; 357: 2122-2128
  2. Berrih-Aknin S, Le Panse R. Myasthenia gravis: A comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun. 2014; 52: 90-100
  3. Berrih-Aknin S, Morel E, Raimond F, et al. The role of the thymus in myasthenia gravis: immunohistological and immunological studies in 115 cases. Ann N Y Acad Sci. 1987; 505: 50-70
  4. Schluep M, Willcox N, Vincent A, et al. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann Neurol. 1987; 22: 212-222
  5. Strobel P, Rosenwald A, Beyersdorf N, et al. Selective loss of regulatory T cells in thymomas. Ann Neurol. 2004; 56: 901-904
  6. Kadota Y, Okumura M, Miyoshi S, et al. Altered T cell development in human thymoma is related to impairment of MHC class II transactivator expression induced by interferon-gamma (IFN-gamma). Clin Exp İmmunol. 2000; 121: 59-68
  7. Baecher-Allan C, Hafler DA. Human regulatory T cells and their role in autoimmune disease. Immunol Rev. 2006; 212: 203-216
  8. Wang HB, Shi FD, Li H, et al. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis. Clin Immunol. 2000; 95: 156-162
  9. Balandina A, Lecart S, Dartevelle P, et al. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood. 2005; 105: 735-741
  10. Luther C, Poeschel S, Varga M, et al. Decreased frequency of intrathymic regulatory T cells in patients with myasthenia-associated thymoma. J Neuroimmunol. 2005; 164: 124-128
  11. Fattorossi A, Battaglia A, Buzzonetti A, et al. Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy. J Clin Immunol. 2008; 28: 194-206
  12. Mu L, Sun B, Kong Q, et al. Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis. Immunology. 2009; 128: e826-836
  13. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008; 28: 454-467
  14. Shi FD, Wang HB, Li H, et al. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol. 2000; 1(3): 245-51
  15. Hao J, Liu R, Piao W, et al. Central nervous system (CNS)- resident natural killer cells suppress Th17 responses and CNS a